Omaha、NEにおける非小細胞肺癌の臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- 他3件
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Oncology Hematology West PC, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #2, Omaha
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University Of Nebraska Medical Center, Omaha
- 他1件
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist, Omaha
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan, Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Omaha
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
被験者募集中第2相
- Research Site, Omaha
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Local Institution - 007-590A, Omaha
- Local Institution - 007-590B, Omaha
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
- 他1件
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
被験者募集中第1相
- Nebraska Cancer Specialists, Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
被験者募集中第1相
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Research Site, Omaha
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
被験者募集中第2相
- University of Nebraska Medical Center, Omaha
Repositioning Immunotherapy in VetArans With Lung Cancer
被験者募集中第2相
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Omaha
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
被験者募集中第1相
- Nebraska Cancer Specialists, Omaha
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Omahaにおける他の研究
- 前立腺がん27件の研究
- 乳がん22件の研究
- がん（全種類）18件の研究
- 大腸癌18件の研究
- 多発性骨髄腫16件の研究
- 卵巣がん14件の研究
- 非ホジキンリンパ腫14件の研究
- 膵臓がん14件の研究
- 転移性癌13件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 悪性黒色腫12件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。